|Continuous versus intermittent β-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials|
JA Roberts, MH Abdul-Aziz, JS Davis, JM Dulhunty, MO Cotta, J Myburgh, ...
American journal of respiratory and critical care medicine 194 (6), 681-691, 2016
|A systematic review of the definitions, determinants, and clinical outcomes of antimicrobial de-escalation in the intensive care unit|
A Tabah, MO Cotta, J Garnacho-Montero, J Schouten, JA Roberts, ...
Clinical infectious diseases 62 (8), 1009-1017, 2016
|The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs|
A Tabah, J De Waele, J Lipman, JR Zahar, MO Cotta, G Barton, JF Timsit, ...
Journal of Antimicrobial Chemotherapy 70 (9), 2671-2677, 2015
|Measuring antimicrobial prescribing quality in Australian hospitals: development and evaluation of a national antimicrobial prescribing survey tool|
R James, L Upjohn, M Cotta, S Luu, C Marshall, K Buising, K Thursky
Journal of Antimicrobial Chemotherapy 70 (6), 1912-1918, 2015
|Attitudes towards antimicrobial stewardship: results from a large private hospital in Australia|
MO Cotta, MS Robertson, M Tacey, C Marshall, KA Thursky, D Liew, ...
Healthcare infection 19 (3), 89-94, 2014
|Antibiotic dose optimization in critically ill patients|
MO Cotta, JA Roberts, J Lipman
Medicina intensiva 39 (9), 563-572, 2015
|Antimicrobial stewardship in Victorian hospitals: a statewide survey to identify current gaps|
RS James, KA McIntosh, SB Luu, MO Cotta, C Marshall, KA Thursky, ...
Medical Journal of Australia 199 (10), 692-695, 2013
|Using periodic point‐prevalence surveys to assess appropriateness of antimicrobial prescribing in A ustralian private hospitals|
MO Cotta, MS Robertson, LM Upjohn, C Marshall, D Liew, KL Buising
Internal medicine journal 44 (3), 240-246, 2014
|Antimicrobial stewardship in Australian hospitals and other settings|
KA Cairns, JA Roberts, MO Cotta, AC Cheng
Infectious diseases and therapy 4 (1), 27-38, 2015
|Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?|
C Mcdonald, MO Cotta, PJ Little, B Mcwhinney, JP Ungerer, J Lipman, ...
Minerva anestesiologica 82 (9), 957-965, 2016
|Implementing antimicrobial stewardship in the Australian private hospital system: a qualitative study|
MO Cotta, MS Robertson, C Marshall, KA Thursky, D Liew, KL Buising
Australian Health Review 39 (3), 315-322, 2015
|Antimicrobial stewardship of β-lactams in intensive care units|
MO Cotta, JA Roberts, A Tabah, J Lipman, D Vogelaers, S Blot
Expert review of anti-infective therapy 12 (5), 581-595, 2014
|Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients|
C Roger, MO Cotta, L Muller, SC Wallis, J Lipman, JY Lefrant, JA Roberts
International journal of antimicrobial agents 50 (2), 227-231, 2017
|We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?|
MO Cotta, JA Roberts, J Lipman
Critical Care 20 (1), 163, 2016
|The use and risks of antibiotics in critically ill patients|
KJ Denny, MO Cotta, SL Parker, JA Roberts, J Lipman
Expert opinion on drug safety 15 (5), 667-678, 2016
|Working Group for Antimicrobial Use in the ICU within the Infection Section of the European Society of Intensive Care Medicine (ESICM). The ADMIN-ICU survey: a survey on …|
A Tabah, J De Waele, J Lipman, JR Zahar, MO Cotta, G Barton
J Antimicrob Chemother 70 (9), 2671-7, 2015
|Should β-lactam antibiotics be administered by continuous infusion in critically ill patients? A survey of Australia and New Zealand intensive care unit doctors and pharmacists|
MO Cotta, JM Dulhunty, JA Roberts, J Myburgh, J Lipman
International journal of antimicrobial agents 47 (6), 436-438, 2016
|Does critical illness change levofloxacin pharmacokinetics?|
JA Roberts, MO Cotta, P Cojutti, M Lugano, G Della Rocca, F Pea
Antimicrobial agents and chemotherapy 60 (3), 1459-1463, 2016
|Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring|
MO Cotta, B Gowen, N Truloff, E Bursle, B McWhinney, JPJ Ungerer, ...
Infectious Diseases 47 (10), 739-742, 2015
|A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.|
J Lipman, SJ Brett, JJ De Waele, MO Cotta, JS Davis, S Finfer, P Glass, ...
Crit Care Resusc 21 (1), 2019